New Products

Apr 12, 2018

St. Jude Cloud

St. Jude Children's Research Hospital, in partnership with DNANexus and Microsoft, has introduced St. Jude Cloud, a public repository of genomics data on pediatric cancer. The St. Jude Cloud platform, which includes free analytics and visualization tools, contains more than 5,000 anonymized whole-genome sequences and 1,200 RNA sequences from young cancer patients. Researchers also are able to upload their own data for analysis and visualization on the cloud-based platform.

Apr 12, 2018

Qiagen AdnaTest ProstateCancerPanel AR-V7 and LungCancer Kits

Qiagen this week launched the AdnaTest ProstateCancerPanel AR-V7 and AdnaTest LungCancer kits at the American Association for Cancer Research annual meeting.

AdnaTest ProstateCancerPanel AR-V7 detects the androgen receptor splice variant 7 in circulating tumor cells (CTCs) of prostate tumor origin isolated from blood samples to investigate potential resistance to drugs for advanced prostate cancer. With an exclusive worldwide license from Johns Hopkins University for nucleic acid detection of the AR-V7 biomarker for diagnostic use, Qiagen is now launching the test for research use.

AdnaTest LungCancer provides insights into the molecular mechanisms of lung cancer through highly specific selection of CTCs, including stem cell-like cells implicated in cancer growth and epithelial-mesenchymal transition, an important marker of cancer therapy resistance. A proprietary set of antibodies provides sensitive detection of lung cancer-associated targets through reverse-transcriptase PCR, and the open system enables users to add targets of interest.

Apr 12, 2018

Fluidigm Advanta CFTR NGS Library Prep Assay

Fluidigm has launched the Advanta CFTR NGS Library Prep Assay, a next-generation sequencing library prep workflow for sequencing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Developed for use with the company's Juno system, the assay automates target enrichment of CFTR variants from each of the gene's 27 exons and selected intronic regions using microfluidic technology. The assay can produce 48 to 1,500 or more NGS libraries each week from DNA derived from blood, saliva, or buccal swabs. Each integrated microfluidic circuit features open inlets to simplify the addition of new assay over time, the company said.

Apr 12, 2018

JPT Peptide Technologies Human Proteome Peptide Catalog

JPT Peptide Technologies announced the launch of its Human Peptide Catalog, a comprehensive online resource for validated reference peptides in mass-spectromety based proteomics. The repository provides quick access to more than 400,000 light and heavy proteotypic peptides covering the majority of the body's proteins. 

Apr 11, 2018

Nanostring Breast Cancer 360 Research Panel

NanoString Technologies has launched the Breast Cancer 360T (BC 360) research panel, which provides a multimodal analysis of tumor gene expression, microenvironment, and immune response. The 770-gene expression panel is the second in a series of 360 panels, following NanoString's PanCancer Immuno-Oncology 360 panel that was launched last year. It includes content across important breast cancer pathways and validated signatures including NanoString's PAM50 signature for breast cancer subtyping and its Tumor Inflammation Signature, as well as other targets involved in DNA damage repair deficiency, inhibitory immune signaling, and immune cell population abundance.

Apr 11, 2018

MNG Laboratories MNGenome

MNG Laboratories has launched a clinical genome product, MNGenome. The test includes whole-genome sequencing to 30x coverage, as well a mitochondrial sequencing and repeat expansion detection. The test has a turnaround time of two to six weeks with a rapid option available for less than two weeks. The Atlanta, Georgia-based clinical laboratory offers the test for trios or proband-only.

Apr 10, 2018

CareDx HeartCare

CareDx has launched HeartCare, a comprehensive rejection surveillance solution for heart transplant recipients. HeartCare includes both AlloMap and AlloSure-Heart results for a holistic view into the health of a heart transplant patient, the company said. The diagnostic gives clinicians indications of patients' immune system activity and graft health

Apr 09, 2018

Golden Helix VSClinical

Golden Helix announced today the upcoming commercial launch of its VSClinical in May 2018. VSClinical will help labs automate their clinical interpretation of variants based on ACMG guidelines. In addition, the firm claims that VSClinical will eliminate problems with human error and individual subjectivity, as well as reduce the time and effort required to sign off on clincal reports. 

Apr 06, 2018

Swift Biosciences Accel-NGS Unique Dual Indexing Kit

Swift Biosciences has announced the release of its Accel-NGS Unique Dual Indexing Kit. Developed in a set of 96 dual indices for both i7 and i5 positions, the indexing kits improve misassignment rates to less than a percent and enable multiple applications including whole-genome sequencing, as well as whole-exome and methylation analysis. In addition, Swift's kits allow a scalable workflow for low-frequency somatic variant discovery, formalin-fixed paraffin-embedded analysis, microbial detection in human samples, and cell-free DNA analysis. The kits are compatible with any Illumina sequencing platform.

Apr 05, 2018

MNG Laboratories Xpress Actionable Epilepsy Panel

MNG Laboratories has announced the commercial launch of its MNG Xpress Actionable Epilepsy panel, a DNA-sequencing assay that uses a standard capture hybridization method to sequence the coding regions of exons. The panel contains a targeted list of 69 epilepsy and seizure-related genes that the company claims are immediately actionable via seizures, pharmacological interventions, and dietary changes. In addition, the panel has a guaranteed turnaround time of less than two weeks for results.   

Apr 03, 2018

LifeMap TGex Version 3.0

LifeMap Sciences has introduced version 3.0 of its TGex clinical genomics platform, featuring interpretation and analysis for structural variations based on phenotypes. The new release draws on the LifeMap Sciences GeneCards human gene database to "score" structural variations according to a patient's phenotype, then provides evidence to help with interpreting links between the gene and the phenotype and other associations. The GeneCards VarElect next-generation sequencing phenotyper supports genome-wide analysis of both copy-number variations and single-nucleotide variations, TGex said.

Mar 30, 2018

Human Longevity Health Nucleus X

Human Longevity this week launched Health Nucleus X and Health Nucleus X Platinum, direct-to-consumer membership-based health products that combine whole-genome sequencing with MRI and other modalities to reveal insights into four disease areas: cancer, cardiac, metabolic, and neurodegenerative/neurovascular. The Health Nucleus is a clinical research and discovery center that relies on the bioinformatics, machine learning, and other technical expertise of the HLI team. By integrating all the data generated through a Health Nucleus visit, clients are given actionable insight into their health, Human Longevity said. The HNX Membership product is $4,950 for the initial membership and $2,950 for subsequent years, and includes WGS, whole-body MRI, and eight other tests. The HNX Platinum Membership is $25,000 for the initial membership and includes two additional years of membership, with membership in subsequent years costing $6,000. In addition to WGS and MRI, the platinum product also includes 15 other tests.

Mar 30, 2018

Foundation Medicine FoundationOne CDx

Foundation Medicine's FoundationOne CDx is now available in the US, following approval by the US Food and Drug Administration last year and finalization of a national coverage determination by the Centers for Medicare and Medicaid Services earlier this month. The test is available for patients with advanced solid tumor cancers. It assesses genomic alterations in 324 cancer genes and serves as a companion diagnostic for patients with certain types of non-small cell lung cancer, melanoma, colorectal cancer, ovarian cancer, and breast cancer to determine if they could benefit from one of 17 on-labeled therapies, of which 12 are approved as first-line therapy for their respective indication. In addition, the test reports genomic biomarkers, such as microsatellite instability and tumor mutational burden that can help inform the use of immunotherapies.

Mar 28, 2018

CellMax Life PD-L1 Test

CellMax Life has added analysis of PD-L1 in circulating tumor cells to its test menu. PD-L1 status is used to determine if a patient might benefit from treatment with cancer immunotherapy drugs. 

Mar 26, 2018

Horizon Discovery Edit-R CRISPRa Arrayed CRISPR RNA Libraries

Horizon Discovery has released the Edit-R CRISPRa arrayed crRNA (CRISPR RNA) libraries, the newest addition to its CRISPR activation reagent platform from the recently acquired Dharmacon business. The new libraries can be used for drug discovery, pathway analysis, and disease progression studies, Horizon said. Edit-R synthetic crRNA arrayed libraries enable one-gene-per-well investigation. They also trigger the endogenous gene's expression, transcribing the gene in its native form.

The Edit-R CRISPRa portfolio includes catalogue libraries for popular human and mouse gene families, such as ubiquitin enzymes, transcription factors, and kinases, in addition to druggable gene targets and the whole human genome. Bespoke collections are also available to support researchers working with a specialized gene target list.

Mar 22, 2018

Color Hereditary Heart Health Test

Color launched its Hereditary Heart Health Test this week. Priced at $249, the test gauges mutations in 30 genes associated with serious hereditary heart conditions that, if detected, can be monitored more closely and treated. The American College of Medical Genetics and Genomics supports testing for these genes. Color said that if patients have mutations in these genes, they can work with their doctors to create a plan to monitor and prevent potentially serious heart events.

Mar 22, 2018

3M Molecular Detection Assay 2- Campylobacter

3M Food Safety announced the release of its new 3M Molecular Detection Assay 2-Campylobacter, with 3M Campylobacter Enrichment Broth, which it believes will provide more efficient testing for a pathogen linked to poultry production. According to the firm, the assay only requires five steps and eliminates the need for microaerophilic incubation, supplements, blood, organic solvents, or autoclaving the broth. 3M noted that the assay is able to perform up to 96 tests of multiple types in a hour-long run.

Mar 20, 2018

Proteomics International Promarker D

Proteomics International Laboratories' partner Omics Global Solutions launched PromarkerD, a predictive diagnostic test for diabetic kidney disease. The test was launched through OMG's distributor in the Dominican Republic, Macrotech Farmaceutica. Proteomics International is in discussions with potential partners to bring the test to the US, Mexico, Japan, Australia, China, and Europe. The test is a mass spec-based laboratory-developed test, Proteomics International said, adding it anticipates another licensing deal for the test with a certified lab in coming weeks. The firm plans on developing an in vitro diagnostic immunoassay version of Promarker D for use in clinical labs. 

Mar 19, 2018

MDNA Life Sciences Mitomic Prostate Test

MDNA Life Sciences has launched the Mitomic Prostate Test Real-Time PCR Kit for research use only in Europe. The liquid biopsy test is designed for the early detection of prostate cancer in advance of biopsy, is independent of PSA and age, and is available for licensee laboratories to conduct in-house validation studies and controlled testing. The assay targets the 3.4-kilobase mitochondrial DNA deletion and is designed for use on real-time PCR platforms. Each kit contains all necessary reagents to process up to 21 patient samples, MDNA said. The company noted that a CE-IVD version of the kit will be available in July.

Mar 15, 2018

Coriell Life Sciences Bacterial Vaginosis Assay

Coriell Life Sciences launched a solution for the quantitative diagnosis and reporting of bacterial vaginosis. Coriell, together with Quantigen, developed the assay and a reporting algorithm that runs on Thermo Fisher Scientific's real-time PCR-based OpenArray technology. The solution provides affordable and comprehensive sample analysis with rapid turnaround times, allowing Coriell to report which microorganisms are present and at what quantities. The test aids in the differential diagnosis of other vaginal infections that clinically present with the same signs and symptoms as bacterial vaginosis, Coriell said.

Mar 13, 2018

Sekisui/Mesa Biotech Silaris Influenza A&B Test

Sekisui Diagnostics has launched the Silaris Influenza A&B test, a 30-minute PCR-based point-of-care assay developed by Mesa Biotech. The test and testing platform were recently cleared by the US Food and Drug Administration and CLIA-waived under the Mesa branding, the Accula Flu A/Flu B. The test system includes a palm-sized dock and disposable test cassettes. Last year Sekisui Diagnostics inked an exclusive contract with Mesa to distribute the system in the US and Canada.

Mar 09, 2018

PierianDx Clinical Genomics Services

PierianDx this week launched clinical genomics services to complement its Clinical Genomics WorkSpace software product. One component of the services involves preparing labs for precision medicine and expanded molecular testing, which includes planning with the clinical team, molecular tumor board development, physician engagement, and integrating technology into LIMS and EMRs. The other component of the services is focused on the clinical lab such as assay validation, selection, and interpretation. The company said that it also offers turnkey and custom assays performed in a CLIA-certified, CAP-accredited laboratory.

Mar 07, 2018

BC Platforms GeneVision

BC Platforms has launched GeneVision software-as-a-service for precision medicine. GeneVision uses the Microsoft Genomics service, which runs on Microsoft Azure, to run several of BC Platforms' existing pipeline technologies to offer scalable, easy-to-use workflows for genotyping and next-generation sequencing, data quality monitoring, and patient report generation starting from raw genome data.

Mar 07, 2018

Pacific Biosciences New Polymerase, Software Release

Pacific Biosciences has launched a new polymerase and a new version of its software for its Sequel instrument. The upgrades increase throughput and performance of the Sequel in applications such as de novo assembly, structural variant detection, targeted sequencing, and RNA sequencing. They enable a throughput of 10 gigabases per SMRT cell for long-insert genomic libraries and up to 20 gigabases per SMRT cell for targeted and RNA sequencing applications.

The new release also improves the sensitivity of Iso-Seq, PacBio's RNA sequencing method, while software enhances help simplify the analytics for multiplexed samples, according to the company.

Mar 06, 2018

Baylor Genetics ClariFind

Baylor Genetics has launched ClariFind, a somatic tumor next-generation sequencing test that analyzes alterations in 277 cancer genes for both solid tumors and hematologic malignancies. The test uses molecular indexing prior to PCR and sequencing to enable the detection of low-frequency mutations. The ClariFind report provides annotated genomic findings, any associated targeted therapies and available clinical trials, and an interpretative summary.

Pages

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.